放疗联合抗PD-1及PD-L1抗体在肿瘤治疗中的进展

Progress of radiotherapy combined with anti-PD-1/PD-L1 in tumor therapy

放疗主要以局部治疗肿瘤被广泛应用于临床,它不仅可以通过损伤DNA直接杀伤肿瘤细胞,而且也对机体的免疫系统产生巨大影响。这种治疗方式不仅有抑制作用,更有激活效应。程序性死亡蛋白-1及其配体-1的抗体作为目前最热门的免疫检查点抑制剂,可通过恢复和提高机体T细胞的免疫杀伤功能抑制肿瘤的增长。随着研究的深入,人们发现二者联合应用治疗肿瘤,疗效较单一治疗模式提高。

Radiotherapy is widely used in local treatment of tumors.It can not only directly kill tumor cells by damaging DNA,but also have a great impact on the immune system of the body.This effect is not only inhibited,but also more activated.Programmed death-1(PD-1)and its ligand 1(PD-L1)antibody,as the most popular immune checkpoint inhibitor,can inhibit tumor growth by restoring and enhancing the immune killing function of T cells.With the deepening of the study,it is found that the combination of the two treatment of tumor,the curative effect is better than the single mode.